CGRP
Reaction mixed to Biohaven’s migraine drug results
March 27, 2018Manufacturing and Production, Research and Development Allergan, Biohaven, CGRP, biotech, drugs, migraine, pharma, pharmaceutical
Biohaven is full of confidence in its lead drug, rimegepant, evidenced only a few weeks ago when it decided to …
Migraine drug bad news hits a weakened Teva
February 9, 2018Medical Communications, Sales and Marketing CGRP, Teva, biotech, drugs, pharma, pharmaceutical
The cacophony of bad news that Teva has received in 2017 really needs no retelling, anyone following the story of …
New breakthrough for CGRP migraine treatments
February 6, 2018Research and Development Allergan, Amgen, CGRP, Novartis, biotech, drugs, pharma, pharmaceutical
Allergan had a rough year in 2017, dropping by close to $80 a share from February 2017 to this month. …
Novartis’ Phase 3 migraine data could revolutionise treatment
November 30, 2017Research and Development CGRP, Novartis Amgen, biotech, drugs, migraine, pharma, pharmaceutical
Descriptions of treatments as ‘revolutionary’ or ‘ground-breaking’ are ten a penny in the pharmaceutical industry, very rarely do such treatments …
Latest content
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
